Exact Sciences - EXAS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $61.57
  • Forecasted Upside: -9.39%
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$67.95
▲ +0.81 (1.21%)

This chart shows the closing price for EXAS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Exact Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EXAS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EXAS

Analyst Price Target is $61.57
▼ -9.39% Downside Potential
This price target is based on 12 analysts offering 12 month price targets for Exact Sciences in the last 3 months. The average price target is $61.57, with a high forecast of $85.00 and a low forecast of $35.00. The average price target represents a -9.39% upside from the last price of $67.95.

This chart shows the closing price for EXAS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 12 polled investment analysts is to buy stock in Exact Sciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings
8/15/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/13/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/11/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
5/12/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 0 sell ratings
8/10/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
11/8/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
1/7/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
2/6/2023

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/18/2023Raymond JamesDowngradeOutperform ➝ Market PerformLow
1/12/2023SVB LeerinkBoost TargetOutperform$70.00 ➝ $75.00Low
1/9/2023Craig HallumBoost Target$35.00 ➝ $44.00Low
1/6/2023SVB LeerinkBoost TargetOutperform$60.00 ➝ $70.00Low
11/14/2022Piper SandlerBoost TargetNeutral$40.00 ➝ $50.00Low
11/7/2022Raymond JamesLower TargetOutperform$70.00 ➝ $60.00Low
11/7/2022BTIG ResearchLower TargetBuy$70.00 ➝ $65.00Low
11/4/2022Robert W. BairdLower Target$75.00 ➝ $60.00Low
11/4/2022CitigroupLower Target$50.00 ➝ $35.00Low
10/19/2022Craig HallumDowngradeBuy ➝ Hold$60.00 ➝ $35.00Low
8/24/2022Credit Suisse GroupInitiated CoverageOutperform$55.00Low
8/17/2022Piper SandlerLower TargetOverweight$50.00 ➝ $40.00Low
8/9/2022Evercore ISIBoost Target$65.00N/A
8/9/2022BenchmarkLower Target$54.00N/A
8/3/2022Raymond JamesLower TargetOutperform$80.00 ➝ $70.00Low
8/3/2022CitigroupLower TargetNeutral$65.00 ➝ $50.00Low
8/3/2022Robert W. BairdLower TargetOutperform$90.00 ➝ $75.00Low
8/3/2022BTIG ResearchLower TargetBuy$100.00 ➝ $70.00Low
8/3/2022CowenLower TargetOutperform$83.00 ➝ $67.00N/A
8/3/2022CowenLower TargetOutperform$83.00 ➝ $67.00Low
8/3/2022Craig HallumLower TargetBuy$81.00 ➝ $60.00Low
7/19/2022CowenSet Target$83.00Low
6/2/2022Piper SandlerInitiated CoverageNeutral$50.00High
4/27/2022Craig HallumLower Target$100.00 ➝ $81.00Low
4/27/2022Robert W. BairdLower Target$100.00 ➝ $90.00High
4/27/2022Raymond JamesLower Target$90.00 ➝ $80.00High
4/27/2022CitigroupLower Target$80.00 ➝ $65.00High
4/19/2022The Goldman Sachs GroupLower TargetBuy$100.00 ➝ $85.00Low
2/23/2022Craig HallumLower Target$133.00 ➝ $100.00High
2/23/2022Raymond JamesLower TargetOutperform$130.00 ➝ $90.00High
2/23/2022Wells Fargo & CompanyLower TargetEqual Weight$95.00 ➝ $80.00High
2/23/2022Robert W. BairdLower Target$116.00 ➝ $100.00High
2/23/2022CitigroupLower TargetNeutral$100.00 ➝ $80.00High
2/23/2022SVB LeerinkLower TargetOutperform$140.00 ➝ $130.00High
11/3/2021BTIG ResearchLower TargetPositive ➝ Buy$145.00 ➝ $120.00High
11/3/2021Craig HallumLower TargetBuy$144.00 ➝ $133.00High
11/3/2021SVB LeerinkLower TargetOutperform$160.00 ➝ $140.00High
11/3/2021Wells Fargo & CompanyLower TargetEqual Weight$120.00 ➝ $95.00High
11/3/2021Robert W. BairdLower TargetOutperform$125.00 ➝ $116.00High
11/3/2021Raymond JamesDowngradeStrong-Buy ➝ Outperform$160.00 ➝ $130.00High
10/14/2021CowenLower TargetOutperform$160.00 ➝ $135.00Low
7/29/2021Stifel NicolausLower TargetBuy$165.00 ➝ $145.00High
7/29/2021BTIG ResearchLower TargetBuy$155.00 ➝ $145.00High
7/29/2021OppenheimerLower TargetOutperform$161.00 ➝ $155.00High
7/29/2021Robert W. BairdLower TargetOutperform$157.00 ➝ $127.00High
7/14/2021SVB LeerinkLower TargetOutperform$170.00 ➝ $160.00High
6/21/2021Wells Fargo & CompanyBoost TargetEqual Weight$115.00 ➝ $120.00Low
6/15/2021Raymond JamesInitiated CoverageStrong-Buy$160.00Medium
6/3/2021The Goldman Sachs GroupInitiated CoverageBuy$160.00Low
5/25/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$115.00Low
5/12/2021Truist FinancialLower TargetBuy$226.00 ➝ $168.00Medium
5/5/2021Craig HallumLower TargetBuy$161.00 ➝ $144.00High
5/5/2021BTIG ResearchLower TargetBuy$175.00 ➝ $155.00High
5/5/2021SVB LeerinkLower TargetOutperform$180.00 ➝ $170.00High
2/18/2021Robert W. BairdLower TargetOutperform$169.00 ➝ $163.00Low
2/17/2021Stifel NicolausBoost TargetBuy$150.00 ➝ $165.00Low
2/17/2021SVB LeerinkBoost TargetMarket Perform ➝ Outperform$170.00 ➝ $180.00Low
2/17/2021CowenBoost TargetOutperform$154.00 ➝ $180.00Low
1/27/2021Truist FinancialInitiated CoverageBuy$226.00 ➝ $226.00Medium
1/21/2021SVB LeerinkBoost TargetOutperform$160.00 ➝ $170.00Medium
10/29/2020UBS GroupDowngradeBuy ➝ Neutral$125.00 ➝ $140.00High
10/28/2020OppenheimerBoost Target$115.00 ➝ $150.00Low
10/28/2020BTIG ResearchBoost Target$140.00 ➝ $155.00Low
10/28/2020Smith Barney CitigroupDowngradeBuy ➝ Neutral$120.00 ➝ $140.00Low
10/28/2020Robert W. BairdBoost TargetPositive ➝ Outperform$135.00 ➝ $150.00Low
10/28/2020SVB LeerinkBoost TargetOutperform$115.00 ➝ $160.00Low
10/28/2020BenchmarkBoost TargetBuy$110.00 ➝ $145.00Low
7/31/2020SVB LeerinkBoost TargetOutperform$90.00 ➝ $115.00High
7/31/2020BenchmarkBoost TargetBuy$90.00 ➝ $110.00Low
7/31/2020CitigroupBoost TargetBuy$110.00 ➝ $120.00Low
7/8/2020OppenheimerReiterated RatingBuyHigh
6/25/2020CitigroupBoost TargetBuy$100.00 ➝ $110.00Medium
5/7/2020Robert W. BairdBoost TargetOutperform$90.00 ➝ $92.00Low
5/7/2020Bank of AmericaBoost TargetBuy$88.00 ➝ $94.00Low
5/7/2020Craig HallumLower TargetIn-Line ➝ Buy$99.00 ➝ $92.00Low
5/7/2020SVB LeerinkLower TargetOutperform$100.00 ➝ $90.00High
4/28/2020UBS GroupLower TargetBuy$135.00 ➝ $115.00High
4/22/2020CitigroupLower TargetBuy$120.00 ➝ $100.00Medium
4/22/2020Robert W. BairdLower TargetOutperform$100.00 ➝ $90.00High
4/21/2020OppenheimerReiterated RatingBuy$115.00Low
4/17/2020Craig HallumLower TargetBuy$127.00 ➝ $99.00High
4/2/2020Stifel NicolausLower TargetBuy$110.00 ➝ $90.00Low
4/2/2020Evercore ISIInitiated CoverageOutperform$70.00High
2/14/2020Stifel NicolausReiterated RatingBuy$110.00N/A
2/12/2020Robert W. BairdReiterated RatingBuyLow
1/10/2020BTIG ResearchInitiated CoverageBuy$127.00High
1/6/2020CitigroupInitiated CoverageBuy$120.00Low
12/13/2019Dougherty & CoInitiated CoverageBuy$120.00Low
11/14/2019Stifel NicolausInitiated CoverageBuy$110.00High
10/31/2019Bank of AmericaReiterated RatingBuy$135.00Medium
10/30/2019SVB LeerinkLower TargetOutperform$133.00 ➝ $105.00Medium
10/30/2019Jefferies Financial GroupLower TargetBuy$138.00 ➝ $120.00High
10/17/2019Bank of AmericaBoost TargetBuy$130.00 ➝ $135.00Low
9/26/2019OppenheimerInitiated CoverageOutperform$130.00Medium
9/24/2019SVB LeerinkReiterated RatingBuyHigh
9/23/2019BenchmarkUpgradeHold ➝ Buy$130.00High
9/10/2019William BlairReiterated RatingBuyLow
8/1/2019UBS GroupBoost TargetBuy$120.00 ➝ $143.00Low
7/30/2019Craig HallumBoost TargetBuy$115.00 ➝ $127.00Medium
7/29/2019CowenBoost TargetOutperform$125.00 ➝ $135.00Low
5/1/2019Jefferies Financial GroupBoost TargetBuy$100.00 ➝ $115.00Low
5/1/2019UBS GroupBoost TargetBuy ➝ Buy$115.00 ➝ $120.00Low
5/1/2019Craig HallumReiterated RatingBuy$95.00 ➝ $115.00Low
5/1/2019BTIG ResearchBoost TargetBuy$130.00Low
4/16/2019UBS GroupBoost TargetBuy ➝ Buy$109.00 ➝ $115.00Low
2/26/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$85.00 ➝ $120.00Medium
2/22/2019UBS GroupSet TargetBuy$109.00Low
2/22/2019Craig HallumSet TargetIn-Line ➝ Buy$77.00 ➝ $95.00High
2/22/2019BTIG ResearchBoost TargetBuy ➝ Positive$110.00High
2/21/2019Robert W. BairdBoost TargetOutperform$90.00 ➝ $102.00High
1/28/2019UBS GroupBoost TargetBuy$100.00 ➝ $109.00Medium
1/7/2019William BlairReiterated RatingOutperformHigh
11/29/2018UBS GroupSet TargetBuy$100.00Low
10/31/2018Jefferies Financial GroupBoost TargetBuy ➝ Buy$74.00 ➝ $84.00Low
10/30/2018UBS GroupSet TargetBuy$100.00High
10/9/2018UBS GroupInitiated CoverageBuy ➝ Buy$100.00Low
9/11/2018Robert W. BairdBoost TargetOutperform ➝ Outperform$74.00 ➝ $85.00Low
9/6/2018Bank of AmericaBoost TargetBuy ➝ Buy$68.00 ➝ $92.00Medium
9/5/2018CowenBoost TargetOutperform$65.00 ➝ $100.00High
9/5/2018BenchmarkReiterated RatingHold ➝ HoldHigh
8/30/2018The Goldman Sachs GroupBoost TargetNeutral$75.00Low
8/23/2018Craig HallumBoost TargetBuy$54.00 ➝ $74.00Medium
8/23/2018Jefferies Financial GroupReiterated RatingBuy$74.00High
8/23/2018SVB LeerinkReiterated RatingOutperform$90.00High
8/23/2018Robert W. BairdBoost TargetOutperform ➝ Outperform$65.00 ➝ $74.00High
8/22/2018BTIG ResearchBoost TargetBuy$95.00High
8/2/2018Jefferies Financial GroupLower TargetBuy ➝ Buy$60.00 ➝ $57.00High
8/2/2018Bank of AmericaLower TargetBuy ➝ Buy$75.00 ➝ $68.00High
8/2/2018Craig HallumLower TargetBuy$60.00 ➝ $54.00High
7/23/2018Bank of AmericaBoost TargetBuy ➝ Buy$67.00 ➝ $75.00Medium
7/18/2018SVB LeerinkReiterated RatingOutperform ➝ Outperform$67.00 ➝ $76.00Low
7/9/2018Robert W. BairdBoost TargetOutperform ➝ Outperform$66.00 ➝ $70.00Low
6/18/2018CowenBoost TargetOutperform$65.00 ➝ $85.00Low
6/5/2018Robert W. BairdBoost TargetOutperform ➝ Outperform$58.00 ➝ $66.00Medium
6/5/2018BTIG ResearchReiterated RatingBuyMedium
5/30/2018BTIG ResearchBoost TargetPositive ➝ Buy$60.00 ➝ $70.00High
4/29/2018BTIG ResearchReiterated RatingBuy$60.00High
4/3/2018BTIG ResearchUpgradeNeutral ➝ BuyLow
3/29/2018William BlairReiterated RatingBuyN/A
3/28/2018SVB LeerinkSet TargetBuy$67.00High
2/27/2018Robert W. BairdUpgradeNeutral ➝ Outperform$42.56 ➝ $56.00Medium
2/23/2018SVB LeerinkSet TargetBuy$67.00High
2/23/2018BenchmarkDowngradeBuy ➝ HoldHigh
2/9/2018SVB LeerinkSet TargetBuy$67.00Medium
(Data available from 2/7/2018 forward)

News Sentiment Rating

0.62 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
7/12/2022
  • 1 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/11/2022
  • 4 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
9/10/2022
  • 3 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
10/10/2022
  • 3 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
11/9/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/9/2022
  • 6 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/8/2023
  • 25 very positive mentions
  • 25 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
2/7/2023

Current Sentiment

  • 25 very positive mentions
  • 25 positive mentions
  • 3 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

Exact Sciences logo
EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.
Read More

Today's Range

Now: $67.95
Low: $65.83
High: $68.17

50 Day Range

MA: $55.74
Low: $41.19
High: $70.77

52 Week Range

Now: $67.95
Low: $29.27
High: $84.31

Volume

497,122 shs

Average Volume

2,982,928 shs

Market Capitalization

$12.07 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Exact Sciences?

The following Wall Street analysts have issued reports on Exact Sciences in the last year: Benchmark Co., BTIG Research, Citigroup Inc., Cowen Inc, Cowen Inc., Craig Hallum, Credit Suisse Group AG, Evercore ISI, Piper Sandler, Raymond James, Robert W. Baird, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., and Wells Fargo & Company.
View the latest analyst ratings for EXAS.

What is the current price target for Exact Sciences?

14 Wall Street analysts have set twelve-month price targets for Exact Sciences in the last year. Their average twelve-month price target is $61.57, suggesting a possible downside of 8.3%. The Goldman Sachs Group, Inc. has the highest price target set, predicting EXAS will reach $85.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $35.00 for Exact Sciences in the next year.
View the latest price targets for EXAS.

What is the current consensus analyst rating for Exact Sciences?

Exact Sciences currently has 5 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EXAS will outperform the market and that investors should add to their positions of Exact Sciences.
View the latest ratings for EXAS.

What other companies compete with Exact Sciences?

How do I contact Exact Sciences' investor relations team?

Exact Sciences' physical mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The medical research company's listed phone number is (608) 284-5700 and its investor relations email address is [email protected] The official website for Exact Sciences is www.exactsciences.com. Learn More about contacing Exact Sciences investor relations.